Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established. may also be used for irrigation of wounds and moistening of wound dressings.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established. may also be used for irrigation of wounds and moistening of wound dressings.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - bee venom 550ug - powder for injection - 550 mcg - active: bee venom 550ug excipient: mannitol sodium chloride albumin phenol sodium chloride sodium octanoate water for injection - albey honey bee venom, wasp venom and yellow jacket venom are indicated for the diagnosis and treatment of hypersensitivity to honey bee venom, wasp venom and yellow jacket venom respectively.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - wasp venom protein 550ug (polistes) - powder for injection - 550 mcg - active: wasp venom protein 550ug (polistes) excipient: mannitol albumin phenol sodium chloride sodium octanoate water for injection - albey honey bee venom, wasp venom and yellow jacket venom are indicated for the diagnosis and treatment of hypersensitivity to honey bee venom, wasp venom and yellow jacket venom respectively.

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - wasp venom protein 550ug (yellow jacket) - powder for injection - 550 mcg - active: wasp venom protein 550ug (yellow jacket) excipient: mannitol albumin phenol sodium chloride sodium octanoate water for injection - albey honey bee venom, wasp venom and yellow jacket venom are indicated for the diagnosis and treatment of hypersensitivity to honey bee venom, wasp venom and yellow jacket venom respectively.

United States - English - NLM (National Library of Medicine)

alk-abello a s - apis mellifera venom (unii: 76013o881m) (apis mellifera venom - unii:76013o881m) - apis mellifera venom 100 ug in 1 ml - the pharmalgen venom preparations are indicated for use in the diagnosis and treatment of hymenoptera sting allergy. the following general considerations should be applied in determining the proper use of these preparations: - approximately two-thirds of adult patients with a history of sting anaphylaxis and a positive venom skin test but who do not receive immunotherapy will experience a systemic reaction if stung by the implicated insect again. these patients should receive therapy4 . children whose reactions have been limited to the skin have an approximately 10% risk of future reactions if stung and not immunized. the nature and severity of these reactions is in general similar to the original reaction and therefore children with this kind of history may not need venom therapy5 . - the risk of anaphylaxis following a future sting is unknown in patients who have been stung without experiencing a systemic reaction but who are currently venom skin test positive. at this time, no recommendation can be made th

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 6 g/l; olive oil, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: nitrogen; water for injections; sodium hydroxide; egg lecithin; sodium oleate; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.